"
The Adverse Event Profile in Patients Treated with TransferonTM (Dialyzable Leukocyte Extracts): A Preliminary Report"
written by Toni Homberg, Violeta Sáenz, Jorge Galicia-Carreón, Iván Lara, Edgar Cervantes-Trujano, Maria C. Andaluz, Erika Vera, Oscar Pineda, Julio Ayala-Balboa, Alejandro Estrada-García, Sergio Estrada-Parra, Mayra Pérez-Tapia, Maria C. Jiménez-Martínez,
published by
Pharmacology & Pharmacy,
Vol.6 No.2, 2015
has been cited by the following article(s):
|
[1]
|
Quality of life in adult patients using dialyzable leukocyte extract for allergic rhinitis
Medicine,
2023
DOI:10.1097/MD.0000000000034186
|
|
|
|
|
[2]
|
Quality of life in adult patients using dialyzable leukocyte extract for allergic rhinitis
Medicine,
2023
DOI:10.1097/MD.0000000000034186
|
|
|
|
|
[3]
|
Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract “Transferon Oral”: The Starting Point to Understand Its Mechanism of Action
Frontiers in Pharmacology,
2020
DOI:10.3389/fphar.2020.569039
|
|
|
|
|
[4]
|
Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit
BioMed Research International,
2019
DOI:10.1155/2019/8980506
|
|
|
|
|
[5]
|
Immunotherapy - Myths, Reality, Ideas, Future
2017
DOI:10.5772/66524
|
|
|
|
|
[6]
|
Dialysable leukocyte extracts in immunotherapy
Biotechnology & Biotechnological Equipment,
2015
DOI:10.1080/13102818.2015.1060136
|
|
|
|